10.2 503B Outsourcing Facilities

Section 503B of the FDCA created a second, distinct category of compounder: the outsourcing facility. Where 503A governs traditional, patient-specific pharmacy compounding, 503B governs large-scale, FDA-registered compounding that can supply hospitals and clinics with stock drugs without an individual prescription. The 503B category was created by the Drug Quality and Security Act (DQSA) of 2013 in direct response to the 2012 New England Compounding Center meningitis outbreak, which exposed the gap between state-board oversight and the scale of some compounding operations.

What Section 503B Establishes

A 503B outsourcing facility is a facility that:

• Is registered with the FDA as an outsourcing facility
• Compounds drugs without a patient-specific prescription (batch compounding and office-use compounding allowed)
• Is subject to current Good Manufacturing Practice (cGMP)
• Is inspected by the FDA on a risk-based schedule
• Pays an annual establishment fee to FDA

The key practical effect is that a 503B facility can make a batch of a common hospital drug — for example, a sterile opioid infusion bag or a ready-to-use local anesthetic — and ship it to a hospital pharmacy to hold as stock, with no prescription tied to an identified patient. This is why 503B output is sometimes called "office use" compounding.

FDA Registration and cGMP

Unlike a 503A pharmacy, a 503B facility is primarily regulated by FDA, not by the state board. The state may still license the facility, but the compounding standards, inspections, and enforcement come from FDA. cGMP is the same manufacturing standard FDA applies to drug manufacturers — covering facility design, environmental monitoring, equipment cleaning, batch records, release testing, and stability. This is a heavier burden than USP <795>/<797>, and it is why 503B products can be used as hospital stock.

Use Cases — Hospital Stock and Shortage Supply

Two dominant use cases drive 503B volume:

1. Hospital stock compounding — hospitals buy ready-to-use sterile products (e.g., prefilled syringes, epidural infusions, cardioplegia) so pharmacy staff do not have to compound every dose on the floor. A 503B facility can supply these as standardized batches.
2. Shortage supply — when a manufacturer discontinues or cannot produce a marketed product (a drug shortage), a 503B facility may compound that drug to keep hospitals supplied, subject to FDA's shortage compounding list and the 503B bulks list.

DSCSA Treatment

503B compounded products, like 503A products, are excluded from DSCSA serialization of the compounded drug. However, the 503B facility itself is a trading partner type under DSCSA and must register with FDA; it must also pass T3 data (transaction information, transaction history, transaction statement) when it distributes non-compounded products. The nuance: the compounded output is not serialized, but the facility is still inside the DSCSA trading-partner framework and is an FDA-registered entity.

503A vs 503B — Full Comparison Table

In Practice

A hospital that buys ready-to-use heparin infusions from a 503B outsourcing facility is buying a batch-made, cGMP-compounded product with no patient-specific prescription. The facility is FDA-registered, FDA-inspected, and pays an annual establishment fee. The compounded heparin bags are not DSCSA-serialized, but the facility itself is a DSCSA trading partner and must register with FDA. Contrast this with a community pharmacy that compounds a single hormone cream against one patient's prescription under 503A — that is state-board regulated, follows USP <795>, and is not FDA-registered.

Worked Example — Why It Matters

Consider a hospital pharmacy during a regional shortage of a sterile beta-lactam infusion. The pharmacy cannot get the manufactured product from its wholesaler. Two compounding paths are open: (a) the hospital's own 503A pharmacy compounds the drug for identified inpatients under USP <797>, or (b) the hospital buys batches from a 503B outsourcing facility. Path (a) ties each bag to a patient and is limited by the pharmacy's sterile capacity; path (b) lets the hospital stock shelves with FDA-registered, cGMP-compounded bags. The 503B facility, not the state board, is the facility regulator, and it can supply multiple hospitals from one batch.